Michael Grimley 1, Vinod Prasad 2, Joanne Kurtzberg 2, Roy Chemaly 3, Thomas Brundage 4, Chad Wilson 4, Herve Mommeja-Marin 4

Size: px
Start display at page:

Download "Michael Grimley 1, Vinod Prasad 2, Joanne Kurtzberg 2, Roy Chemaly 3, Thomas Brundage 4, Chad Wilson 4, Herve Mommeja-Marin 4"

Transcription

1 Twice-weekly Brincidofovir (BCV, CMX1) Shows Promising Antiviral Activity in Immunocompromised Transplant Patients with Asymptomatic Adenovirus Viremia Michael Grimley 1, Vinod Prasad, Joanne Kurtzberg, Roy Chemaly 3, Thomas Brundage, Chad Wilson, Herve Mommeja-Marin 1 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Duke University Medical Center, Durham, NC, 3 MD Anderson Cancer Center, Houston, TX, Chimerix, Inc., Durham, NC.

2 Disclosures CMX1-35 Expanded Access Protocol was funded in part with Federal funds from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO1O1113C. Michael Grimley - None

3 Adenovirus (AdV) AdV is a serious and often fatal viral infection in immunocompromised patients, especially in hematopoietic cell transplant (HCT) recipients Estimated annual incidence of AdV infections in HCT recipients ranges from 5 to 5%, and is increasing, likely secondary to increased use of T cell depleted allografts and cord blood as a donor source Mortality rate of up to % No antiviral drugs are currently approved for treatment of AdV infections, but due to the high mortality, cidofovir is used in spite of the high risk of renal injury or renal failure Sources: Ljungman P, Eur J Clin Microbiol Infect Disease. Nihal G et al, BBMT 1. Florescu DF et al, BBMT 1 3

4 Brincidofovir (BCV, CMX1) Orally bioavailable lipid-conjugate of the nucleotide analog cidofovir (CDV) High intracellular concentration of the active antiviral cidofovirdiphosphate (CDV-PP) with a long t 1/ up to -.5 days Broad spectrum in vitro activity against dsdna viruses 5-fold more potent against AdV than CDV in vitro EC 5 <. um No evidence of nephrotoxicity Not a substrate of organic anion transporter 1 (OAT-1) No renal dysfunction in > subjects who have received BCV to date Enrollment started in August 13 in the Phase 3 SUPPRESS* trial for the prevention of CMV in HCT recipients * CMX1-31 ClinicalTrials.gov: NCT17917 Source: Beadle et al, AAC : :31-.

5 BCV Development Program Timeline Study 35: Large number of EIND requests led to initiation of Expanded Access Study 35. Study 35: N=1 Nov 1 - Oct 1 EINDs: N=3; March 9 - March 1 CMV, AdV, BKV, EBV, HSV, JCV, HHV, VZV, HPV Study : Design based on EIND and Study 35 experience and success of preemptive therapy in CMV. Data reported September 13 (Grimley et al, ICAAC). Study : N= June 11 - Feb 13 AdV preemption

6 Brincidofovir Expanded Access Program BCV access for patients with life-threatening dsdna viral infections and no therapeutic options Emergency INDs (EINDs): N>3, n=11 database, n=3 AdV 1+ centers in US, Canada, France, UK, Austria, Switzerland, Spain, Israel and Chile Adult and pediatric patients with CMV, AdV, BKV, EBV, HSV, JCV, HHV, VZV or HPV March 9 March 1 (with limited exceptions since) Expanded Access Study 35* (N=1 total, n= AdV) 3 US sites, conducted from November 1 October 1 November 1 July 11: all dsdna viruses included July 11 October 1: Enrollment limited to CMV, HSV or AdV Program currently inactive *CMX1-35: ClinicalTrials.gov: NCT11311

7 Study 35: Overview Eligibility: Immediate life-threatening or serious disease or condition caused by infection with one or more dsdna virus (Sponsor approval required) Subjects received BCV twice weekly (BIW) for 3 months or until virology assessments of any previously positive culture or PCR sites yield negative tests for successive weeks 1 mg BIW or mg QW for adults (tablet) mg/kg BIW or mg/kg QW for children (liquid) treatment may have been continued for up to a total of months Central laboratory plasma AdV viral load measurements Baseline (BL): subjects may have qualified based on local results During treatment (weekly, at discretion of investigator) post treatment week 1 and week BIW = twice weekly, QW=once weekly 7

8 Study 35: All-cause mortality lower when BCV was begun for AdV viremia vs disseminated AdV ---- Viremia ****** Localized ---- Disseminated p =.1 Presented at European Group for Blood and Marrow Transplantation Annual Meeting, April 13

9 Study : Overview Primary objective: To evaluate the safety and efficacy of early intervention with BCV versus placebo to prevent the development of AdV disease in HCT recipients Randomized, double-blind, placebo-controlled study at 9 US transplant centers (June 11-February 13) Based on successful identification of early disease in CMV reactivation, targeted identification of asymptomatic AdV viremia Enrolled pediatric and adult allogeneic HCT recipients with asymptomatic AdV viremia (serum AdV PCR 1 copies/ml) Subjects received BCV BIW or QW or placebo for -1 weeks 1 mg BIW or mg QW for adults (tablet) mg/kg BIW or mg/kg QW for children (liquid) CMX1- ClinicalTrials.gov: NCT113 9

10 Study : Study Design 735 patients screened for AdV viremia patients with AdV viremia 1 copies/ml Stratified by ALC < 3 or 3 cells/mm 3 BCV BIW BCV QW Placebo ALC = absolute lymphocyte count 1

11 Baseline Characteristics BIW n=1 35 BIW n=1 Combined n= Age range, years < 1 9 (%) (7%) 17 (5%) 1-17 (1%) (%) > 17 3 (1%) (33%) 7 (7%) Female, % 5 (3%) (5%) 11 (%) Baseline median weight (range), kg 7 (1-9) 3 (9-19) 31 (9-19) Baseline median ALC (range), cells/mm 3 3 (-15) 1 (-) 35 (-) Baseline GVHD, % (9%) 3 (5%) 7 (7%) Time from transplant to first BCV dose, days -<1 1 (71%) 7 (5%) 17 (5%) (1%) 1 (%) (15%) > 1 1 (7%) (33%) 5 (19%) Baseline median AdV Viremia (range), copies/ml 15 (BLD-7.7x1 ) (1-.x1 7 ) 37 (BLD-.x1 7 ) Co-infected with other dsdna virus(es) (57%) 5 (%) 13 (5%) GVHD = graft versus host disease, BLD = below the lower limit of detection (1 copies/ml) 11

12 Transplant Characteristics BIW n=1 35 BIW n=1 Combined n= Reason for transplant Malignancies (9%) 7 (5%) 11 (%) Non-malignant diseases 1 (71%) 5 (%) 15 (5%) Conditioning / Manipulation Myeloablative (3%) (7%) 1 (5%) Reduced intensity 7 (5%) (17%) 9 (35%) T-cell depletion 1 (%) 1 (%) None 1 (7%) 1 (%) (%) Source of graft Bone marrow (1%) (%) Peripheral blood stem cells (3%) (33%) 1 (3%) Cord blood (3%) (33%) 1 (3%) Lung 1 (%) 1 (%) Unknown HCT source 3 (5%) 3 (1%) Type of graft Haploidentical 3 (1%) 3 (1%) Related donor 1 (7%) 1 (%) (%) Unrelated donor 1 (71%) 7 (5%) 17 (5%) Autologous (17%) (%) Unknown type (17%) (%) 1

13 Anti-viral Therapy and Follow-up 35 BCV BIW exposure Median Days (Range): (-99) 35 Prior IV cidofovir within 3 days of enrollment 5/1 subjects (%) Median Days (Range): 15 (1-) BCV BIW exposure Median Days (Range): (11-91) Subjects were followed for a median weeks (range: 3 to 7 weeks) after first dose 13

14 AdV Viremia Rapid Response to BCV BIW BIW n=1 35 BIW n=1 Combined BCV BIW n= AdV Viral Load Log1 copies/ml Days AdV Viral Load Log1 copies/ml Days AdV Viral Load Log1 copies/ml Days LLOD LLOD = Assay lower limit of detection (1 copies/ml) 1

15 Low Level AdV Viremia Resolves Spontaneously (1 to 1 copies/ml at Baseline) Placebo BCV BIW 1 1 Log 1 copies/ml 1 Log 1 copies/ml Log 1 copies/ml 1 Log 1 copies/ml Log 1 copies/ml Log 1 copies/ml Day Relative to First Dose Day Relative to First Dose 15

16 High Level AdV Viremia Suppressed with BCV BIW (> 1 copies/ml at Baseline) Placebo BCV BIW 1 1 Log 1 copies/ml 1 Log 1 copies/ml Log 1 copies/ml 1 Log 1 copies/ml Log 1 copies/ml 1 Log 1 copies/ml Day Relative to First Dose Day Relative to First Dose 1

17 AdV Response Combined BCV BIW Baseline AdV 1 c/ml n=7* Baseline AdV >1 c/ml n=1* LLOD within first week of treatment, % (%) (57%) LLOD any time on treatment, % 7 (1%) 11 (79%) Median (range) time to LLOD, days (7-) 9 (-11) Mean (SD) decrease in viremia, log 1 c/ml.3 (.) 1. (1.3) Placebo Baseline AdV 1 c/ml n=1* Baseline AdV >1 c/ml n=* LLOD within first week of treatment, % 5 (5%) (5%) LLOD any time on treatment, % 9 (9%) 5 (3%) Median (range) time to LLOD, days (-7) 15 (-5) Mean (SD) decrease in viremia, log 1 c/ml.1 (.) 1.1 (1.5) * Detectable AdV at central lab at Baseline, c/ml=copies/ml, LLOD=Assay lower limit of detection (1 copies/ml) 17

18 Non-relapse Mortality BCV BIW (n=1) 35 BCV BIW (n=1) Placebo (n=1) 1

19 Non-Relapse Causes of Death Combined BCV BIW / (15%) Intracranial hemorrhage secondary to HHV- meningitis and fungal meningitis Coagulase-negative Staphylococcus pneumonia Pseudomonas aeruginosa septic shock Toxoplasmosis and Aspergillus infection Baseline AdV Viremia (copies/ml) Minimum AdV Viremia (copies/ml) Last AdV Viremia (copies/ml) 7.7x1 5.1x1 1.7x1 Undetectable Undetectable Undetectable Not done Undetectable 3.x1 3.9x1 5 3.x1 5 3.x1 5 Placebo 5/1 (%) Baseline AdV Viremia (copies/ml) Minimum AdV Viremia (copies/ml) Last AdV Viremia (copies/ml) Grade agvhd, HHV- encephalitis.x1 5 Undetectable Undetectable Multiple organ failure secondary to septic shock (AdV and liver microabcesses)*.1x1.9x1 5.9x1 5 Aspiration pneumonia 35 Undetectable Undetectable Multiple organ failure secondary to graft failure and Enterococcus sepsis* 1 Undetectable 7 Respiratory failure of unknown origin, with proven AdV enteritis* x1 *Received open label BCV 19

20 Conclusions Brincidofovir BIW rapidly decreased AdV viremia in most patients and limited progression to non-relapse mortality in high risk transplant recipients Responses from the randomized trial Study are similar to that of the more heterogeneous study population in the expanded access Study 35 dsdna = double-stranded DNA

21 Adenovirus and Future Trials Adenovirus viremia at any level may not be an appropriate singular marker for early adenovirus disease independent of clinical risk assessment or other compartments (e.g., GI, respiratory) Prospective PCR Monitoring Reveals Adenovirus Viremia is Associated with a Significant Risk of AdV Disease in T-Cell Depleted and Cord Blood Allograft Recipients, Huang et al. (BMT Tandem 1) Analyses of clinical risks and other predictors of progression may need to be included in future interventional trials of brincidofovir in patients at increased risk of adenoviral infection Prevention of primary or reactivated adenovirus infection is likely to be a more efficient approach to decrease mortality related to AdV infection in at-risk transplant recipients dsdna = double-stranded DNA 1

IDWeek 2014, Session: 186, Late Breaker Oral Abstracts Saturday, October 11, 2014, Presentation No. LB 3

IDWeek 2014, Session: 186, Late Breaker Oral Abstracts Saturday, October 11, 2014, Presentation No. LB 3 IDWeek 2014, Session: 186, Late Breaker Oral Abstracts Saturday, October 11, 2014, Presentation No. LB 3 Preliminary Safety Results and Antiviral Activity from the Open label Pilot Portion of a Phase 3

More information

Chimerix, Inc., Durham, NC; 5 Duke University Medical Center, Durham, NC

Chimerix, Inc., Durham, NC; 5 Duke University Medical Center, Durham, NC Improved Outcomes in Allogeneic Hematopoietic Cell Transplant Patients Treated with Brincidofovir (CMX001, BCV) for Disseminated Adenovirus Disease Compared to Literature: Updated Preliminary Results from

More information

Dedicated to Preventing and Treating Life-Threatening Viral Infections. Randall Lanier Vice President, Biology

Dedicated to Preventing and Treating Life-Threatening Viral Infections. Randall Lanier Vice President, Biology Dedicated to Preventing and Treating Life-Threatening Viral Infections Randall Lanier Vice President, Biology Adenovirus: Epidemiology and Treatment Options Allogeneic hematopoietic cell transplant (allo

More information

IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS WITH BRINCIDOFOVIR: FINAL 36 WEEK RESULTS FROM THE ADVISE TRIAL

IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS WITH BRINCIDOFOVIR: FINAL 36 WEEK RESULTS FROM THE ADVISE TRIAL TREATMENT OF ADENOVIRUS (AdV) INFECTION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS WITH BRINCIDOFOVIR: FINAL 36 WEEK RESULTS FROM THE ADVISE TRIAL Vinod K. Prasad, MD, FRCP 1, Genovefa A. Papanicolaou,

More information

BRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS

BRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS BRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS Diana F. Florescu, MD 1, Michael S. Grimley, MD 2, Genovefa

More information

Switch from Existing Antivirals to Brincidofovir Leads to Improving Renal Function

Switch from Existing Antivirals to Brincidofovir Leads to Improving Renal Function Switch from Existing Antivirals to Brincidofovir Leads to Improving Renal Function Marion Morrison MD 1, Robin Avery MD 2, Eun Kwak MD 3, Tom Brundage MS 1, Herve Mommeja-Marin MD 1 2014 World Transplant

More information

2016 BMT Tandem Meetings

2016 BMT Tandem Meetings ASBMT CIBMTR 2016 BMT Tandem Meetings for Prevention of Cytomegalovirus after Allogeneic Hematopoietic Cell Transplantation in CMV-Seropositive Patients A Randomized, Double-Blind, -Controlled, Parallel-Group

More information

DEDICATED TO PREVENTING AND TREATING LIFE-THREATENING VIRAL INFECTIONS

DEDICATED TO PREVENTING AND TREATING LIFE-THREATENING VIRAL INFECTIONS DEDICATED TO PREVENTING AND TREATING LIFE-THREATENING VIRAL INFECTIONS February 22, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements

More information

Emerging CMV Resistance Profile for CMX001

Emerging CMV Resistance Profile for CMX001 Emerging CMV Resistance Profile for CMX001 International Conference on Antiviral Research May 15, 2013 Randall Lanier, PhD Forward Looking Statements These slides and the accompanying oral presentation

More information

ACTIVITY OF BRINCIDOFOVIR (BCV) AGAINST MURINE POLYOMAVIRUS (MUPYV) IN A MOUSE INFECTION MODEL

ACTIVITY OF BRINCIDOFOVIR (BCV) AGAINST MURINE POLYOMAVIRUS (MUPYV) IN A MOUSE INFECTION MODEL ACTIVITY OF BRINCIDOFOVIR (BCV) AGAINST MURINE POLYOMAVIRUS (MUPYV) IN A MOUSE INFECTION MODEL Kidney Week 2018 Poster # SA-PO642 BRINCIDOFOVIR(BCV) DEMONSTRATES ANTIVIRAL ACTIVITY AGAINST MURINE POLYOMAVIRUS

More information

JP MORGAN HEALTHCARE CONFERENCE M. MICHELLE BERREY, MD, MPH CHIEF EXECUTIVE OFFICER JANUARY 10, 2019

JP MORGAN HEALTHCARE CONFERENCE M. MICHELLE BERREY, MD, MPH CHIEF EXECUTIVE OFFICER JANUARY 10, 2019 JP MORGAN HEALTHCARE CONFERENCE M. MICHELLE BERREY, MD, MPH CHIEF EXECUTIVE OFFICER JANUARY 10, 2019 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking

More information

HC WAINWRIGHT 20 TH ANNUAL GLOBAL INVESTMENT CONFERENCE GARRETT NICHOLS, MD, MS CHIEF MEDICAL OFFICER SEPTEMBER 6, 2018

HC WAINWRIGHT 20 TH ANNUAL GLOBAL INVESTMENT CONFERENCE GARRETT NICHOLS, MD, MS CHIEF MEDICAL OFFICER SEPTEMBER 6, 2018 HC WAINWRIGHT 20 TH ANNUAL GLOBAL INVESTMENT CONFERENCE GARRETT NICHOLS, MD, MS CHIEF MEDICAL OFFICER SEPTEMBER 6, 2018 Forward-Looking Statements These slides and the accompanying oral presentation contain

More information

Dedicated to Preventing and Treating Life-Threatening Viral Infections. W. Garrett Nichols, MD, MS Chief Medical Officer

Dedicated to Preventing and Treating Life-Threatening Viral Infections. W. Garrett Nichols, MD, MS Chief Medical Officer Dedicated to Preventing and Treating Life-Threatening Viral Infections W. Garrett Nichols, MD, MS Chief Medical Officer Chimerix: Dedicated to Discovering, Developing and Commercializing Antivirals to

More information

Virological Surveillance in Paediatric HSCT Recipients

Virological Surveillance in Paediatric HSCT Recipients Virological Surveillance in Paediatric HSCT Recipients Dr Pamela Lee Clinical Assistant Professor Department of Paediatrics & Adolescent Medicine Queen Mary Hospital LKS Faculty of Medicine, The University

More information

Disclosures. Investigator-initiated study funded by Astellas

Disclosures. Investigator-initiated study funded by Astellas Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development

More information

Current and Future Treatment of Cytomegalovirus Infection

Current and Future Treatment of Cytomegalovirus Infection Current and Future Treatment of Cytomegalovirus Infection Robin K. Avery MD, FIDSA, FAST Professor of Medicine, Division of Infectious Disease Johns Hopkins Disclosures Robin Avery MD has been a co-investigator

More information

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital

More information

Diagnosis of CMV infection UPDATE ECIL

Diagnosis of CMV infection UPDATE ECIL UPDATE ECIL-4 2011 Recommendations for CMV and HHV-6 management in patients with hematological diseases Per Ljungman, Rafael de la Camara, Hermann Einsele, Dan Engelhard, Pierre Reusser, Jan Styczynski,

More information

1Q2018 EARNINGS CALL MAY 7, 2018

1Q2018 EARNINGS CALL MAY 7, 2018 1Q2018 EARNINGS CALL MAY 7, 2018 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information within the meaning of the Private Securities

More information

PUO in the Immunocompromised Host: CMV and beyond

PUO in the Immunocompromised Host: CMV and beyond PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation

More information

Multi-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant

Multi-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant Multi-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant Hanley PJ, Krance BR, Brenner MK, Leen AM, Rooney CM, Heslop HE, Shpall EJ, Bollard CM Hematopoietic Stem Cell Transplantation

More information

2017 CST-Astellas Canadian Transplant Fellows Symposium. Optimizing use of organs from Increased Risk Donors

2017 CST-Astellas Canadian Transplant Fellows Symposium. Optimizing use of organs from Increased Risk Donors 2017 CST-Astellas Canadian Transplant Fellows Symposium Optimizing use of organs from Increased Risk Donors Atual Humar, MD Atul Humar is a Professor in the Department of Medicine, University of Toronto.

More information

Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1

Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1 Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,

More information

ORIGINAL ARTICLE. Timothy K. Tippin, PhD, Marion E. Morrison, MD, Thomas M. Brundage, MS, and Hervé Momméja-Marin, MD

ORIGINAL ARTICLE. Timothy K. Tippin, PhD, Marion E. Morrison, MD, Thomas M. Brundage, MS, and Hervé Momméja-Marin, MD ORIGINAL ARTICLE Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies Timothy K. Tippin, PhD,

More information

Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multivirus-Specific T Cells (Viralym-M)

Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multivirus-Specific T Cells (Viralym-M) OFF-THE-SHELF T CELL THERAPY FOR CANCER PATIENTS FOLLOWING STEM CELL TRANSPLANT Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multivirus-Specific T Cells (Viralym-M) Ann M.

More information

Revista Cubana de Hematología, Inmunología y Hemoterapia. 2017; 36 (Suplemento).

Revista Cubana de Hematología, Inmunología y Hemoterapia. 2017; 36 (Suplemento). Depletion of TCR alpha/beta+ T-lymphocytes from grafts for haplo haematopoietic CELL transplantation (HCT) in children Heilmann C, Ifversen M, Haastrup E, Fischer-Nielsen A. Haematopoietic Cell Transplantation

More information

New proposals for WHO International Standards for Human Herpesvirus 6 and Adenovirus

New proposals for WHO International Standards for Human Herpesvirus 6 and Adenovirus New proposals for WHO International Standards for Human Herpesvirus 6 and Adenovirus Jacqueline Fryer Division of Virology, NIBSC National Institute for Biological Standards and Control Assuring the quality

More information

Disclosure. Objectives 1/22/2015

Disclosure. Objectives 1/22/2015 Evaluation of the Impact of Anti Thymocyte Globulin (ATG) on Post Hematopoietic Stem Cell Transplant (HCT) Outcomes in Patients Undergoing Allogeneic HCT Katie S. Kaminski, PharmD, CPP University of North

More information

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient 1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical

More information

Cytomegalovirus in critically ill patients

Cytomegalovirus in critically ill patients ! Cytomegalovirus in critically ill patients Frédéric Pène Medical ICU, Hôpital Cochin, AP-HP, Paris, France Université Paris Descartes, Sorbonne Paris Cité Institut Cochin, Inserm U1016, CNRS UMR-8104

More information

Sample Selection- Vignettes

Sample Selection- Vignettes Sample Selection- Vignettes Rangaraj Selvarangan, BVSc, PhD, D(ABMM) Professor, UMKC School of Medicine Director, Microbiology, Virology and Molecular Infectious Diseases Laboratory Director, Laboratory

More information

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow 5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL

More information

Lung Injury after HCT

Lung Injury after HCT Lung Injury after HCT J. Douglas Rizzo, MD, MS Financial Disclosure None SCS06_1.ppt Background HCT an important therapeutic modality for malignant and non-malignant diseases Pulmonary Toxicity common

More information

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000

More information

Haplo vs Cord vs URD Debate

Haplo vs Cord vs URD Debate 3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor

More information

4nd Patient and Family Day

4nd Patient and Family Day 4nd Patient and Family Day EBMT Slide template Barcelona 7 February 2008 EBMT 2010 Vienna, Austria ; www.ebmt.org History of Stem Cell Transplantation Appelbaum et al, NEJM 2006 What is EBMT? Scientific,

More information

Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation

Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation Find Studies About Studies Submit Studies Resources About Site Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation

More information

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state

More information

Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA

Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes

More information

Potential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections.

Potential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections. In the name of God Principles of post Tx infections 1: Potential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections. Infection processes can progress

More information

INCIDENCE OF ADENOVIRUS INFECTIONS IN PEDIATRIC AND ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS IN EUROPE

INCIDENCE OF ADENOVIRUS INFECTIONS IN PEDIATRIC AND ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS IN EUROPE INCIDENCE OF ADENOVIRUS INFECTIONS IN PEDIATRIC AND ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS IN EUROPE Sebastian Voigt, 1 Cécile Pochon, 2 Kanchan Rao, 3 Antonio Pérez-Martínez, 4 Marco

More information

Please submit supporting medical documentation, notes and test results.

Please submit supporting medical documentation, notes and test results. Pharmacy Prior Authorization AETA BETTER HEALTH FLORIDA Valcyte (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.

More information

Dr. Joseph McGuirk Professor of Medicine, BMT Medical Director, Interim Director, Division of Hematology/Oncology

Dr. Joseph McGuirk Professor of Medicine, BMT Medical Director, Interim Director, Division of Hematology/Oncology Advances in Autologous and Allogeneic Stem Cell Transplantation Dr. Joseph McGuirk Professor of Medicine, BMT Medical Director, Interim Director, Division of Hematology/Oncology April 12, 2014 Disclosures

More information

Transpla. antation. Associate Professor of Medical Virology Virology Research Center Shahid Beheshti University of Medical Sciences

Transpla. antation. Associate Professor of Medical Virology Virology Research Center Shahid Beheshti University of Medical Sciences Viral Mo olecular Diagno osis in Transpla antation Seyed Alireza Nadji, Ph.D. Associate Professor of Medical Virology Virology Research Center Shahid Beheshti University of Medical Sciences Which techniques

More information

Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016

Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016 Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this

More information

Management of Viral Infections in HCT

Management of Viral Infections in HCT Management of Viral Infections in HCT Alison Coats, APRN-BC Liza Rodriguez, APRN, AOCNP Objectives Recognize viral infections that affect patients after hematopoietic cell transplant (HCT) Describe the

More information

EBV in HSCT 2015 update of ECIL guidelines

EBV in HSCT 2015 update of ECIL guidelines ECIL-6 EBV in HSCT 2015 update of ECIL guidelines Jan Styczynski (Poland, chair), Walter van der Velden (Netherlands), Christopher Fox (United Kingdom), Dan Engelhard (Israel), Rafael de la Camara (Spain),

More information

Infections after stem cell transplantation

Infections after stem cell transplantation Infections after stem cell transplantation Lidia Gil Poznan, Poland No conflict of interest Lisbon, Portugal 20/03/2018 #EBMT18 www.ebmt.or Infections after HSCT Infectious complications universal problem

More information

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal

More information

What s a Transplant? What s not?

What s a Transplant? What s not? What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence

More information

Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association

Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association Els Vandecasteele, Jan De Waele, Dominique Vandijck, Stijn Blot, Dirk

More information

Blood Components & Indications for Transfusion. Neda Kalhor

Blood Components & Indications for Transfusion. Neda Kalhor Blood Components & Indications for Transfusion Neda Kalhor Blood products Cellular Components: Red blood cells - Leukocyte-reduced RBCs - Washed RBCs - Irradiated RBCs Platelets - Random-donor platelets

More information

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant

More information

Recommendations for VZV management in. Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman

Recommendations for VZV management in. Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman Recommendations for VZV management in patients Cas cliniques with leukemia Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman Introduction Acute

More information

Haploidentical Transplantation today: and the alternatives

Haploidentical Transplantation today: and the alternatives Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks

More information

Is in vitro T-cell depletion necessary for Haploidentical TransplantationTitle of Presentation. Disclosure of Interest: Nothing to Disclose

Is in vitro T-cell depletion necessary for Haploidentical TransplantationTitle of Presentation. Disclosure of Interest: Nothing to Disclose Rupert Handgretinger Children s University Hospital, Tübingen, Germany Is in vitro T-cell depletion necessary for Haploidentical TransplantationTitle of Presentation Disclosure of Interest: Nothing to

More information

OTKA azonosító: Típus: K Vezető kutató: Gergely Lajos

OTKA azonosító: Típus: K Vezető kutató: Gergely Lajos Human herpesvirus 6 (HHV-6), mostly variant B reactivation in renal transplant patients has been published previously, but the pathogenetic role of HHV-6 variant A has not been clarified. During the project

More information

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte

More information

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014 Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of

More information

Should CMV infection post allo SCT be treated by cell-based therapy?

Should CMV infection post allo SCT be treated by cell-based therapy? Shoud CMV infection post ao SCT be treated by ce-based therapy? CMV Prof. Per Ljungman Department of Hematoogy Karoinska University Hospita Stockhom, Sweden The fight! Antivira drugs Ce therapy How can

More information

Riposta immune versus stato immune

Riposta immune versus stato immune Riposta immune versus stato immune Russell E. Lewis U.O. Malattie Infettive, Policlinico S. Orsola-Malpighi Dipartimento di Scienze Mediche e Chirurgiche Alma Mater Studiorum Università di Bologna Immunodeficiency

More information

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize

More information

Donatore HLA identico di anni o MUD giovane?

Donatore HLA identico di anni o MUD giovane? Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events

More information

Viral disease prevention after hematopoietic cell transplantation

Viral disease prevention after hematopoietic cell transplantation (2009) 44, 471 482 & 2009 Macmillan Publishers Limited All rights reserved 0268-3369/09 $32.00 www.nature.com/bmt GUIDELINES Viral disease prevention after hematopoietic cell transplantation J Zaia 1,

More information

BMTCN REVIEW COURSE PRE-TRANSPLANT CARE

BMTCN REVIEW COURSE PRE-TRANSPLANT CARE BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts

More information

ESCMID Postgraduate Education Course Infectious Diseases in Pregnant Women, Fetuses and Newborns Bertinoro, Italy 3 7 October 2010

ESCMID Postgraduate Education Course Infectious Diseases in Pregnant Women, Fetuses and Newborns Bertinoro, Italy 3 7 October 2010 ESCMID Postgraduate Education Course Infectious Diseases in Pregnant Women, Fetuses and Newborns Bertinoro, Italy 3 7 October 2010 Robert Pass University of Alabama at Birmingham School of Medicine Disclosures:

More information

CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints

CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential

More information

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions

More information

Reduced-intensity Conditioning Transplantation

Reduced-intensity Conditioning Transplantation Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,

More information

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,

More information

Causes of Death. J. Douglas Rizzo, MD MS February, New11_1.ppt

Causes of Death. J. Douglas Rizzo, MD MS February, New11_1.ppt Causes of Death J. Douglas Rizzo, MD MS February, 2012 New11_1.ppt Overview Attribution of COD important for research purposes Frequently not correctly coded or completely reported Source of confusion

More information

Overview of New Approaches to Immunosuppression in Renal Transplantation

Overview of New Approaches to Immunosuppression in Renal Transplantation Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute

More information

Long-Term Outcomes After Hematopoietic Cell Transplantation

Long-Term Outcomes After Hematopoietic Cell Transplantation Long-Term Outcomes After Hematopoietic Cell Transplantation Conflicts of Interest No relevant financial conflicts of interest Navneet Majhail, MD, MS Medical Director, NMDP Assistant Scientific Director,

More information

Diagnosingneurotropicvirus infectionsin immunocompromised individuals

Diagnosingneurotropicvirus infectionsin immunocompromised individuals Molecular Virology Unit, Microbiology and Virology Dept IRCCS Policlinico San Matteo, Pavia DptClinical and Surgical Sciences, Diagnostics and Pediatrics University of Pavia Diagnosingneurotropicvirus

More information

4100: Cellular Therapy Essential Data Follow-Up Form

4100: Cellular Therapy Essential Data Follow-Up Form 4100: Cellular Therapy Essential Data Follow-Up Form Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: Visit: 100 day 6 months 1 year 2 years >2 years, Specify:

More information

Abstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ

Abstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract

More information

3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)

3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) 3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day

More information

An Overview of Blood and Marrow Transplantation

An Overview of Blood and Marrow Transplantation An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit

More information

The Pulmonary Pathology of Iatrogenic Immunosuppression. Kevin O. Leslie, M.D. Mayo Clinic Scottsdale

The Pulmonary Pathology of Iatrogenic Immunosuppression. Kevin O. Leslie, M.D. Mayo Clinic Scottsdale The Pulmonary Pathology of Iatrogenic Immunosuppression Kevin O. Leslie, M.D. Mayo Clinic Scottsdale The indications for iatrogenic immunosuppression Autoimmune/inflammatory disease Chemotherapy for malignant

More information

EBMT Society EBMT. History Organisation Studies Activity Philosophy. EBMT Website. European Group for Blood and Marrow Transplantation

EBMT Society EBMT. History Organisation Studies Activity Philosophy. EBMT Website. European Group for Blood and Marrow Transplantation EBMT EBMT Organisation and Activities J Apperley 13th. ESH-EBMT Training Course Targu Mures May 24 26, 2010 History Organisation Studies Activity Philosophy EBMT Website www.ebmt.org EBMT Society European

More information

Bone Marrow Transplantation and the Potential Role of Iomab-B

Bone Marrow Transplantation and the Potential Role of Iomab-B Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation

More information

An Introduction to Bone Marrow Transplant

An Introduction to Bone Marrow Transplant Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,

More information

Abstract. Introduction

Abstract. Introduction ORIGINAL ARTICLE VIROLOGY Diagnostic value of quantitative PCR for adenovirus detection in stool samples as compared with antigen detection and cell culture in haematopoietic stem cell transplant recipients

More information

Appendix E1. Epidemiology

Appendix E1. Epidemiology Appendix E1 Epidemiology Viruses are the most frequent cause of human infectious diseases and are responsible for a spectrum of illnesses ranging from trivial colds to fatal immunoimpairment caused by

More information

UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE

UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE Naynesh Kamani, M.D. Children s National Medical Center GW University School of Medicine Washington, DC SCD scope of problem in USA Commonest

More information

Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT

Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT History Why is blood transfusion involved? What tests are performed in blood transfusion and why? What does a protocol look

More information

Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017

Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017 Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell Ann Haight, MD 9 Sept 2017 Spoiler alert Yes (we have a cure) And No Work to do! 2 Sickle Cell Treatment Options Supportive Care

More information

Use of Viral Load Testing in Managing CMV Infections in SOTR

Use of Viral Load Testing in Managing CMV Infections in SOTR Use of Viral Load Testing in Managing CMV Infections in SOTR Angela M. Caliendo, MD, PhD, FIDSA Professor and Vice Chair, Medicine Alpert Medical School of Brown University Providence, RI Disclosures Scientific

More information

Copyright information:

Copyright information: Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation

More information

UCBT as Risk Factor for HHV- 6 Pale

UCBT as Risk Factor for HHV- 6 Pale Viral Infec,ons a/er Hematopoie,c Cell Transplanta,on Michael Boeckh, MD Fred Hutchinson Cancer Research Center University of Washington SeaFle, WA, USA Important Viral Infec,ons CMV HHV- 6 Adenovirus

More information

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,

More information

Severe Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia

Severe Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia Severe Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia Liat Shragian Alon, MD Rabin Medical Center, ISRAEL #EBMT15 www.ebmt.org Patient: 25-year-old male No prior medical history

More information

Le infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy

Le infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Le infezioni fungine nel trapianto di cellule staminali emopoietiche Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Potential conflicts of interest Received grants as speaker/moderator

More information

Stem Cell Transplantation for Severe Aplastic Anemia

Stem Cell Transplantation for Severe Aplastic Anemia Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center

More information

Rapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Transplantation

Rapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Transplantation Rapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Subtitel Transplantation Boelens/Nierkens lab Jaap Jan Boelens, Central Immune

More information

Rob Wynn RMCH & University of Manchester, UK. HCT in Children

Rob Wynn RMCH & University of Manchester, UK. HCT in Children Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action

More information

EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal

More information

Complications after HSCT. ICU Fellowship Training Radboudumc

Complications after HSCT. ICU Fellowship Training Radboudumc Complications after HSCT ICU Fellowship Training Radboudumc Type of HSCT HSCT Improved outcome due to better HLA matching, conditioning regimens, post transplant supportive care Over one-third have pulmonary

More information

LETERMOVIR (MK-8228): OVERVIEW OF PIVOTAL PHASE 3 STUDY (P001) ASSESSING PROPHYLAXIS OF LETERMOVIR VS. PLACEBO IN ALLOGENEIC HSCT RECIPIENTS

LETERMOVIR (MK-8228): OVERVIEW OF PIVOTAL PHASE 3 STUDY (P001) ASSESSING PROPHYLAXIS OF LETERMOVIR VS. PLACEBO IN ALLOGENEIC HSCT RECIPIENTS LETERMOVIR (MK-8228): OVERVIEW OF PIVOTAL PHASE 3 STUDY (P001) ASSESSING PROPHYLAXIS OF LETERMOVIR VS. PLACEBO IN ALLOGENEIC HSCT RECIPIENTS October 6, 2017 Cyrus Badshah, MD, PhD Director, Clinical Research

More information

Disclosures. Franco Locatelli Advisory Board, Bellicum Pharmaceuticals, Inc. Lakshmanan Krishnamurti No disclosures. David Jacobsohn.

Disclosures. Franco Locatelli Advisory Board, Bellicum Pharmaceuticals, Inc. Lakshmanan Krishnamurti No disclosures. David Jacobsohn. Administration of Rivogenlecleucel (rivo-cel; BPX-51) Cells Following αβ-t and B-cell-Depleted HLA Haploidentical HSCT (haplo-hsct) in Children With Acute Leukemias Franco Locatelli, 1 Annalisa Ruggeri,

More information